Cited by 135Statistical Methods in Clinical TrialsAcute Ischemic Stroke ManagementStatistical Methods in Epidemiology

Treatment effects for which shift or binary analyses are advantageous in acute stroke trials

Open access

Abstract

BACKGROUND: In acute stroke trials, functional outcome may be analyzed by dichotomizing ordinal outcome scales or by evaluating the entire scale range (shift analysis). The conditions under which shift or binary analysis will be more efficient have not been previously well delineated. METHODS: Model randomized clinical trials employing the modified Rankin Scale of global handicap were constructed to reflect 1) mild benefits experienced across all ranges of stroke severity (neuroprotective effect), 2) substantial benefits across all ranges of stroke severity (early recanalization effect), 3) substantial benefits across wide range of stroke severity but with limited ability to achieve fully normal outcome (late recanalization effect), 4) benefits clustered at unexpected health state transitions. RESULTS: In neuroprotective models, shift analysis was the most efficient technique in detecting a treatment effect. In the early recanalization models, dichotomization at excellent outcome and shift analysis were of comparable efficiency, both superior to dichotomization at good outcome. In the late recanalization models, dichotomization at good outcome performed best, shift analysis less well, and dichotomization at excellent outcome poorly. In the unexpected benefits model, shift analysis substantially outperformed dichotomization analyses. These patterns held among the seven actual acute trials reporting full range Rankin outcomes and showing treatment benefit identified in the literature. CONCLUSIONS: The pattern of treatment effect of the intervention determines whether shift analysis or simple dichotomized analysis will be more efficient. Shift analysis is especially advantageous when treatments confer a relatively uniform, mild benefit to patients over a wide range of stroke severities or confer benefits at unexpected but clinically important health state transitions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000341308.73506.b7

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
  2. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Eryth- ropoietin therapy for acute stroke is both safe and benefi- cial. Mol Med 2002;8:495-505.
  3. Saver JL. Novel end point analytic techniques and inter- preting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055-3062.
  4. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statisti- cal reanalysis of functional outcomes in stroke trials. Stroke 2007;38:1911-1915.
  5. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007;38:3205-3212.
  6. Rankin J. Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J 1957;2:200-215.
  7. Samsa G, Matchar D, Goldstein L, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998;136:703- 713.
  8. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-1541.
  9. Lampl Y, Zivin JA, Fisher M, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 2007;38:1843-1849.
  10. Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Ja- pan. Stroke 2007;38:2633-2639.
  11. Stingele R, Bluhmki E, Hacke W. Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial? Cerebrovasc Dis 2001;11:30-33.
  12. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: a randomized controlled trial: Prolyse in Acute Ce- rebral Thromboembolism. JAMA 1999;282:2003-2011.
  13. Berge E, Barer D. Could stroke trials be missing important treatment effects? Cerebrovasc Dis 2002;13:73-75.
  14. White IR, Thompson SG. Choice of test for comparing two groups, with particular application to skewed out- comes. Stat Med 2003;22:1205-1215.
  15. Walters SJ. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36. Health Qual Life Out- comes 2004;2:1-17.
  16. Stokes ME, Davis CS, Koch GG. Categorical Data Analy- sis Using the SAS System, 2nd Edition. Cary, NC: SAS Institute Inc., 2000.

Cited by

Sorted by citations

Authors
Saver, J. L., & Gornbein, J.
Affiliations
University of California, Los Angeles (US)
Venue
Neurology
Published
2009-04-14
Volume
72
Issue
15
Pages
1310-1315
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2061570300
Cited by
135
References
2
Citations by year
2026: 6 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 13 · 2020: 9 · 2019: 6 · 2018: 16 · 2017: 8 · 2016: 3 · 2015: 10 · 2014: 6 · 2013: 9 · 2012: 8
FWCI
7.58
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • FibroGen
  • Novo Nordisk
  • Astellas Pharma
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (U01NS044364, U01 NS44364, P50NS044378)
  • Core Research for Evolutional Science and Technology
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
Keywords
acute stroke, shift analysis, dichotomization, modified Rankin Scale, functional outcome, statistical efficiency, neuroprotection, recanalization, health state transitions
MeSH terms
Acute Disease, Data Interpretation, Statistical, Humans, Placebos, Models, Statistical, Randomized Controlled Trials as Topic, Treatment Outcome, Sample Size, Stroke, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review